🔍

GPT Healthcare Limited (GPTHEALTH)

₹140.74 +0.68% last close, 16 Oct

📊 NSE: GPTHEALTH 🏢 Healthcare 📢 Latest filing: 08 Oct 2026 📝 Analysis written: 13 Dec 2025

Latest quarterly results (Q1 FY27)

In its latest reported quarter, Q1 FY27, GPT Healthcare's revenue was ₹126 Cr (+17.8% year on year, +0.0% on the previous quarter), and net profit ₹13.0 Cr (+62.5% year on year); the operating margin was 19.0%.

Q1 FY27 (₹ Cr)	Value	YoY vs Q1 FY26	QoQ
Revenue	₹126	+17.8%	+0.0%
Operating profit	₹24.0	+41.2%	+4.3%
Net profit	₹13.0	+62.5%	-13.3%
EPS (₹)	1.55	+64.9%	-12.9%
Operating margin	19.0%	—	—

Full quarterly financials → Results calendar →

GPTHEALTH delivery percentage

NSE end-of-day data for Fri, 16 Oct 2026

On Fri, 16 Oct 2026, 53.59% of the GPTHEALTH shares traded on NSE were taken to delivery, against the stock's own 20-session average of 54.9%. That is close to its usual level. Turnover was only ₹84 lakh, so a handful of trades can move this figure.

53.59%Delivery, 16 Oct

54.9%Own 20-session average

0.5×Volume vs its average

₹140.74NSE close · +0.68%

Delivery in the last 5 sessions: 51.5% · 52.9% · 58.8% · 60.3% · 53.6%

Delivery across the market →

A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed

📢 Recent Corporate Announcements

GPT Healthcare Submits Reg 74(5) Demat Compliance Certificate for Q2 FY27

🟡 NEUTRAL ⭐ 1/10

ROUTINE 📅 08 Oct 2026, 05:10 PM

GPT Healthcare Limited submitted its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026. The Registrar and Share Transfer Agent, MUFG Intime India Private Limited, confirmed that no requests for dematerialization or rematerialization of shares were received during the quarter. This filing is purely statutory and procedural in nature. It carries no operational or financial impact on the company.

Regulation 74(5) compliance submitted for the quarter ended September 30, 2026
RTA MUFG Intime India confirmed zero demat/remat requests received during the period
Filing verified and submitted on October 8, 2026

💡 No action required; investors should track upcoming Q2 FY27 financial results and operational updates for business developments.

66% PAT Growth in Q1 FY27; GPT Healthcare Reports 18.2% Revenue Increase

🟢 POSITIVE ⭐ 6/10

EARNINGS 📅 07 Aug 2026, 07:46 PM

GPT Healthcare reported a strong Q1 FY27 with total income rising 18.2% and PAT surging 66% YoY. While overall network occupancy stood at 45.5%, mature hospitals maintained a healthier 58.07%, reflecting the initial ramp-up phase of the newly commissioned Raipur facility which reached 17% occupancy. ARPOB improved to ₹42,350, driven by a shift toward high-end tertiary care and robotic surgeries. Management expects the Dumdum facility to reach 70% occupancy by Q3 FY27 and is targeting approximately 10 liver transplants annually at the Raipur unit.

PAT increased by 66% YoY during Q1 FY27, significantly outpacing revenue growth.
Total income grew by 18.2% YoY, supported by a 31% revenue jump at the Howrah facility.
Average Revenue Per Occupied Bed (ARPOB) improved to ₹42,350 across the network.
Mature hospital occupancy (excluding Raipur) remained steady at 58.07%.
Raipur facility achieved NABH accreditation in a record 13 months with occupancy rising to 17% from 7% YoY.

💡 Monitor the occupancy ramp-up at the Raipur facility and the management's ability to sustain ARPOB growth through complex surgeries. Investors should also track the execution timeline for the Ranchi hospital planned for FY28.

GPT Healthcare: Shareholders Approve Rs 1.50 Final Dividend and 90% Director Consultancy Fee Sharing

🟡 NEUTRAL ⭐ 4/10

ROUTINE 📅 07 Aug 2026, 05:28 PM

GPT Healthcare shareholders approved all resolutions at the 37th AGM held on August 6, 2026. Key approvals include a final dividend of Rs 1.50 per share, bringing the total FY26 payout to Rs 2.50 per share (approx. 1.57% yield). A significant special resolution was passed regarding consultancy fees for Dr. Ghanshyam Goyal, a Non-Executive Director, allowing for a 90% fee-sharing model for consultations. The meeting saw 70.88% voting participation, with nearly 100% approval for most items, including the re-appointment of Dr. Aruna Tantia.

Approved a final dividend of Rs 1.50 per share, resulting in a total FY26 dividend of Rs 2.50 per share.
Passed a special resolution for Dr. Ghanshyam Goyal (Non-Executive Director) to receive 90% sharing on OPD/IPD consultation fees.
Approved remuneration for Dr. Mridul Tantia (VP and relative of Director) with 58,117,986 votes in favor.
Total voting turnout was 70.88% of the 82,054,823 total shares outstanding.
Fixed fees for Bariatric cases were set at Rs 20,000 to Rs 25,000 depending on room category for Dr. Ghanshyam Goyal.

💡 Investors should monitor the dividend credit timeline and the operational ramp-up of the Raipur hospital, which is key to achieving the company's 11% projected growth rate.

GPT Healthcare Declares ₹1.50 Final Dividend at 37th AGM; Total FY26 Dividend at ₹2.50

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 06 Aug 2026, 08:36 PM

GPT Healthcare concluded its 37th Annual General Meeting on August 6, 2026, where shareholders approved a final dividend of ₹1.50 per share. This brings the total dividend for FY25-26 to ₹2.50 per share, which is notable given the FY26 EPS of ₹2.08. The meeting also covered the adoption of FY26 audited financials (Revenue: ₹227.27 Cr, PAT: ₹17.05 Cr) and the re-appointment of several directors. Additionally, shareholders considered resolutions for remuneration and consultancy fees for three related-party medical professionals.

Final dividend of ₹1.50 (15%) declared, bringing total FY26 dividend to ₹2.50 per share
66 members attended the meeting, representing 65.60% of the company's shareholding
FY26 Audited Financial Statements adopted with a reported revenue of ₹227.27 Cr and PAT of ₹17.05 Cr
Shareholders voted on the re-appointment of Independent Directors Mr. Hari Modi and Dr. Tapti Sen
Approval sought for professional fees and remuneration for three related-party individuals (Dr. Mridul Tantia, Dr. Niharika Tantia, and Dr. Ghanshyam Goyal)

💡 Investors should monitor the final voting results to be published within 2 working days to confirm the approval of related-party remuneration and director re-appointments.

GPT Healthcare Releases Q1 FY27 Earnings Call Audio Recording

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 04 Aug 2026, 02:11 PM

GPT Healthcare has released the audio recording of its investor conference call held on August 4, 2026, to discuss the un-audited financial results for the quarter ended June 30, 2026. The call follows a period where the company expanded its installed capacity to 719 beds, up from 561 in FY25. Management's discussion likely centered on the ramp-up of the Raipur facility and the decline in occupancy rates to 44.70% in H1 FY26 due to this new capacity. This filing is a standard regulatory requirement under SEBI LODR regulations.

Conference call conducted on August 4, 2026, at 11:00 AM IST regarding Q1 FY27 results
Installed capacity increased to 719 beds in H1 FY26 from 561 beds in FY25
Bed occupancy rate stood at 44.70% in H1 FY26, down from 53.76% in H1 FY25 due to capacity addition
Average Length of Stay (ALOS) improved slightly to 3.49 days from 3.51 days YoY
Company maintains a market capitalization of ₹1349 Cr with a TTM revenue of ₹227 Cr

💡 Investors should review the recording for management's specific commentary on the Raipur hospital's path to monthly breakeven and updates on the Ranchi expansion planned for FY28.

GPT Healthcare Q1 FY27: PAT Surges 65.7% YoY to ₹12.7 Cr with 20.4% EBITDA Margin

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 05:31 PM

GPT Healthcare reported a strong start to FY27 with total income rising 18% YoY to ₹128.2 Cr. Profitability saw a significant boost as PAT jumped 65.7% YoY to ₹12.7 Cr, supported by EBITDA margins expanding 300 bps to 20.4%. While overall occupancy stood at 45.5% due to the new Raipur facility, mature hospitals maintained a higher occupancy of 58.07%. The company is aggressively expanding, with the Jamshedpur hospital on track for Q4 FY27 and a 7th facility in the works to take total capacity beyond 1,000 beds.

Total Income grew 18% YoY to ₹128.2 Cr, representing approximately 27% of the total FY26 revenue.
EBITDA increased 38.5% YoY to ₹26.2 Cr, with margins improving from 17.4% to 20.4%.
PAT surged 65.7% YoY to ₹12.7 Cr, despite a 12.6% sequential decline from Q4 FY26.
Raipur facility received a liver transplant license and is projected to reach breakeven by Q3 FY27.
Expansion plans are on track to increase total network capacity from 719 beds to over 1,000 beds.

💡 Investors should monitor the occupancy ramp-up at the Raipur facility and the timely commissioning of the Jamshedpur hospital in Q4 FY27. The ability to maintain 20%+ EBITDA margins as new capacity comes online will be a key performance indicator.

65.7% PAT Growth in Q1 FY27; GPT Healthcare Targets 1,000+ Beds in Two Years

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 05:22 PM

GPT Healthcare reported a strong Q1 FY27 with revenue growing 17.8% YoY to ₹126.2 Cr. Profit After Tax (PAT) surged 65.7% YoY to ₹12.7 Cr, driven by an 11% improvement in ARPOB to ₹42,350 and higher clinical complexity. While overall occupancy stood at 45.5%, mature hospitals maintained 58.07% occupancy. The newly commissioned Raipur facility (158 beds) is on track for operational breakeven by Q3 FY27, supporting the company's roadmap to reach a 1,000-bed capacity by FY27-28.

Revenue from operations increased 17.8% YoY to ₹126.2 Cr in Q1 FY27.
EBITDA grew 38.5% YoY to ₹26.2 Cr, with margins expanding to 20.4% from 17.4% in the previous year.
Average Revenue Per Occupied Bed (ARPOB) rose to ₹42,350, supported by 800+ cumulative robotic surgeries.
Raipur hospital contributed ₹10.6 Cr to revenue in Q1 FY27 despite a low 17.4% occupancy rate.
Company maintains a long-term ROCE target of approximately 25% through disciplined asset utilization.

💡 Investors should monitor the occupancy ramp-up at the Raipur facility and the execution timeline for the Ranchi hospital (planned for FY28) to validate the 1,000-bed expansion strategy.

GPTHEALTH Q1 FY27: PAT Jumps 65.7% YoY to ₹12.73 Cr on 17.8% Revenue Growth

🟢 POSITIVE ⭐ 7/10

EARNINGS 📅 03 Aug 2026, 04:38 PM

GPT Healthcare reported a strong year-on-year performance for Q1 FY27, with revenue from operations growing 17.8% to ₹126.20 crore. Net profit surged 65.7% YoY to ₹12.73 crore, driven by improved operational efficiencies as total expenses grew at a slower rate (13.8%) than revenue. Sequentially, revenue remained flat compared to Q4 FY26, while PAT declined from ₹14.57 crore primarily due to a significant deferred tax credit in the preceding quarter. The company maintained healthy margins with EBITDA improving to approximately 20.7% from 17.6% in the same period last year.

Revenue from operations increased 17.8% YoY to ₹126.20 crore from ₹107.11 crore.
Profit After Tax (PAT) grew 65.7% YoY to ₹12.73 crore compared to ₹7.68 crore in Q1 FY26.
Basic EPS for the quarter rose to ₹1.55 from ₹0.94 in the year-ago period.
Total expenses for the quarter stood at ₹111.07 crore, representing 88% of revenue vs 91% in Q1 FY26.
Other income grew 29.6% YoY to ₹2.03 crore.

💡 Monitor the occupancy levels at the newly commissioned Raipur facility, as the company targets a 13-14 month breakeven timeline. Investors should also track progress on the Ranchi hospital expansion planned for FY27-28 to reduce geographic concentration.

GPT Healthcare to Host Q1 FY27 Earnings Call on August 4, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 25 Jul 2026, 02:12 PM

GPT Healthcare Limited has scheduled its earnings conference call for Tuesday, August 4, 2026, at 11:00 AM IST to discuss financial results for the quarter ended June 30, 2026. The call will involve senior management including the Group CFO and Executive Director. This follows a period where the company expanded its capacity to 719 beds. Investors will be looking for updates on the Raipur hospital's breakeven progress and occupancy trends, which stood at 44.70% in H1 FY26.

Earnings call scheduled for August 4, 2026, at 11:00 AM IST
Focus on Un-Audited Financial Results for the 1st quarter ended June 30, 2026
Management participation includes Group CFO Mr. Atul Tantia and Executive Director Mr. Anurag Tantia
Company recently increased installed capacity to 719 beds from 561 beds in FY25
Discussion likely to cover the 11% expected growth rate and Raipur facility ramp-up

💡 Monitor the Q1 FY27 financial results and management commentary on August 4 regarding the Raipur hospital's occupancy levels and the progress of the Ranchi expansion planned for FY28.

0 demat requests reported by GPT Healthcare for the quarter ended June 30, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 11 Jul 2026, 11:47 AM

GPT Healthcare Limited has submitted its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. For the quarter ended June 30, 2026, the company's Registrar and Transfer Agent, MUFG Intime India Private Limited, confirmed that zero requests for dematerialization or rematerialization of shares were received. This is a standard procedural filing required by SEBI to ensure the integrity of shareholding records. There is no financial impact on the company's operations or earnings.

Zero (0) requests for dematerialization or rematerialization were received during the quarter.
The reporting period ended on June 30, 2026.
The filing is made under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.
The Registrar and Transfer Agent is MUFG Intime India Private Limited with SEBI Registration Number INR000004058.

💡 This is a procedural update; investors should monitor the company's upcoming quarterly financial results for fundamental performance.

₹1.50 Final Dividend: GPT Healthcare Sets July 30 as Record Date for 37th AGM

🟡 NEUTRAL ⭐ 5/10

DIVIDEND 📅 09 Jul 2026, 05:59 PM

GPT Healthcare has scheduled its 37th Annual General Meeting for August 6, 2026, and confirmed a final dividend of ₹1.50 per share (15% of face value) for FY25-26. The record date for dividend eligibility and e-voting is July 30, 2026, with payments to be completed by September 4, 2026. This dividend represents a payout of approximately 72% of the TTM EPS of ₹2.08. Investors can now access the full Annual Report for FY25-26 via the company's website.

Final dividend of ₹1.50 per equity share (15% of ₹10 face value) announced for FY25-26.
Record date for dividend and e-voting eligibility set for July 30, 2026.
37th Annual General Meeting (AGM) scheduled for August 6, 2026, at 3:00 PM IST.
Dividend payment to be processed on or before September 4, 2026.
Annual Report for FY25-26 released, detailing the expansion to 719 beds from 561 beds.

💡 Investors should review the Annual Report for updates on the Raipur hospital's breakeven timeline and the Ranchi expansion project. Ensure bank details are linked to KYC-compliant folios by July 30 to receive the dividend.

GPT Healthcare sets Aug 6 for AGM; Final Dividend of ₹1.50 per share announced

🟢 POSITIVE ⭐ 6/10

DIVIDEND 📅 09 Jul 2026, 04:33 PM

GPT Healthcare has scheduled its 37th Annual General Meeting (AGM) for August 6, 2026. The company has proposed a final dividend of ₹1.50 per share (15% of face value), which, combined with the ₹1.00 interim dividend, brings the total FY26 payout to ₹2.50 per share. The record date for the final dividend is July 30, 2026, with payment to be completed by September 4, 2026. Additionally, the meeting will seek approval for remuneration increases for related-party medical professionals.

Final dividend of ₹1.50 per equity share (15% on face value of ₹10) proposed for FY2025-26
Total dividend for the year reaches ₹2.50 per share including the ₹1.00 interim dividend already paid
Record date for dividend eligibility and e-voting cut-off set for July 30, 2026
Proposed salary hike for Dr. Mridul Tantia (VP) to ₹5,00,000 per month with a ceiling of ₹10,00,000
Minimum guarantee professional fee of ₹2,00,000 per month proposed for Dr. Niharika Tantia (Consultant)

💡 Investors should note the July 30 record date for dividend eligibility and monitor the AGM voting results regarding related-party remuneration approvals.

GPT Healthcare Announces Trading Window Closure from July 1, 2026 for Q1 Results

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 27 Jun 2026, 12:55 PM

GPT Healthcare Limited has informed the exchanges that its trading window for dealing in company securities will be closed for designated persons starting July 1, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the announcement of un-audited financial results for the quarter ending June 30, 2026. The window will remain closed until 48 hours after the results are declared. This is a standard procedural requirement and does not impact business operations.

Trading window closure commences on Wednesday, July 01, 2026
Window to remain closed until 48 hours after the declaration of Q1 FY2026-27 results
Company reported a TTM revenue of Rs 227 Cr and a PAT of Rs 17 Cr
Installed capacity recently increased to 719 beds in H1 FY26 from 561 beds in FY25

💡 Investors should monitor the upcoming announcement of the board meeting date for Q1 FY27 results to assess the ramp-up of the Raipur hospital and occupancy trends.

GPT Healthcare Launches 'Saksham Niveshak' Campaign for Unclaimed Dividends and KYC

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 08 Jun 2026, 06:33 PM

GPT Healthcare Limited has initiated the 'Saksham Niveshak' campaign, running from April 1, 2026, to July 9, 2026, following Ministry of Corporate Affairs guidelines. The initiative is designed to help shareholders claim unpaid dividends and update KYC details to prevent the mandatory transfer of shares and funds to the Investor Education and Protection Fund (IEPF). On June 8, 2026, the company dispatched formal communications to all affected shareholders. Investors must submit required forms such as ISR-1 and SH-13 to the Registrar and Transfer Agent, MUFG Intime India Private Limited.

The 'Saksham Niveshak' campaign is active from April 1, 2026, through July 9, 2026.
Aims to facilitate the recovery of unpaid dividends and prevent asset transfer to the IEPF.
Company dispatched notification letters to shareholders with unclaimed dividends on June 8, 2026.
Requires submission of KYC documents including PAN, bank details, and nomination forms to RTA MUFG Intime India.

💡 Shareholders should check the 'unpaid/unclaimed dividend' list on the company's website and ensure their KYC and bank details are updated with the RTA to avoid loss of dividends.

GPT Healthcare to Participate in InsightX 2026 Virtual Investor Conference on June 11

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 05 Jun 2026, 04:29 PM

GPT Healthcare Limited has scheduled a virtual group meeting with institutional investors and fund managers for June 11, 2026, at 3:00 PM IST. The company will be participating in the 'InsightX 2026 - Choice Virtual Conference' to engage with the investment community. Management intends to use the existing Q4FY26 Investor Presentation, which is already in the public domain, for the discussion. The company has explicitly stated that no unpublished price sensitive information (UPSI) will be shared during this interaction.

Virtual group meeting scheduled with institutional investors and fund managers on June 11, 2026.
Participation in the InsightX 2026 - Choice Virtual Conference starting at 3:00 PM IST.
Discussion will focus on the previously released Q4FY26 Investor Presentation.
Company confirms that no unpublished price sensitive information will be disclosed during the meet.

💡 Investors should monitor the company's website for any post-event transcripts or updated presentations that may provide further clarity on the management's outlook for FY27.

View All GPTHEALTH Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Revenue from operations grew by 11% YoY in H1 FY26 to INR 226 Cr, compared to INR 204 Cr in H1 FY25. Q2 FY26 revenue grew by 12.5% YoY to INR 118.9 Cr. The growth is primarily driven by healthcare services across in-patient and out-patient departments.

Geographic Revenue Split

Revenue is highly concentrated in West Bengal, Tripura, and Raipur (Chhattisgarh). West Bengal and Tripura are the primary contributors, though specific percentage splits per state are not disclosed.

Profitability Margins

PAT margin stood at 8% in H1 FY26 (INR 18.3 Cr), a decline from 11.4% in H1 FY25. FY25 PAT margin was 12.0% (INR 50 Cr). The decline in H1 FY26 is attributed to higher depreciation and finance costs associated with new hospital commissioning.

EBITDA Margin

EBITDA margin was 18.8% in H1 FY26 (INR 43 Cr), down from 22.3% in H1 FY25. This 350 bps compression is largely due to an operating loss of INR 3-4 Cr at the newly commissioned Raipur hospital which is yet to reach breakeven.

Capital Expenditure

The company has planned a capital expenditure of INR 50 Cr over the medium term for hospitals in Ranchi and Raipur. Historical fresh issue proceeds of INR 40 Cr in February 2024 were used for debt prepayment and corporate purposes.

Credit Rating & Borrowing

CRISIL has assigned a 'Stable' outlook. Borrowing costs are supported by low gearing (0.4 time in 2023) and low bank limit utilization of 4%. Interest coverage remains healthy despite finance costs rising to INR 3.80 Cr in H1 FY26 from INR 1.6 Cr in H1 FY25.

⚙️ Operational Drivers

Raw Materials

Medical consumables, pharmacy drugs, and surgical implants represent the primary variable costs, categorized under 'Other expenses' which stood at INR 102.3 Cr in H1 FY26 (45% of revenue).

Capacity Expansion

Current installed capacity increased to 719 beds in H1 FY26 from 561 beds in FY25. Planned expansion includes a new asset-light hospital in Ranchi expected by FY2027-28.

Raw Material Costs

Other expenses (including medical consumables) increased to 45.2% of revenue in H1 FY26 from 42.6% in H1 FY25. Procurement is managed through internal controls to sustain operating margins between 21-22% in mature units.

Manufacturing Efficiency

Bed occupancy rate was 44.70% in H1 FY26, down from 53.76% in H1 FY25, due to the addition of new capacity at Raipur. Average Length of Stay (ALOS) improved to 3.49 days from 3.51 days YoY.

📈 Strategic Growth

Expected Growth Rate

11%

Growth Strategy

Growth will be achieved through the ramp-up of the Raipur hospital, which is expected to breakeven monthly by the 13th-14th month at 25% occupancy. Future growth is anchored on the Ranchi hospital (FY28) and increasing ARPOB (which grew from INR 29,671 to INR 32,947 in FY24) by launching new medical specialties.

Products & Services

Healthcare services including In-patient (IPD) treatments, Out-patient (OPD) consultations, surgical procedures, and pharmacy sales.

Brand Portfolio

GPT Healthcare, ILS Hospitals.

New Products/Services

New medical specialties at existing hospitals and the full-scale launch of the Raipur facility are expected to contribute significantly to the projected 8-10% EBITDA margin for new units in FY27.

Market Expansion

Expansion into Raipur (commissioned Q4 FY25) and Ranchi (planned for FY2027-28) to reduce geographic concentration in West Bengal.

Market Share & Ranking

Established market position in Eastern India; specific ranking not disclosed.

🌍 External Factors

Industry Trends

The industry is shifting toward asset-light models and increased insurance penetration. GPTHEALTH is positioning itself by expanding into underserved Tier-2 cities like Raipur and Ranchi.

Competitive Landscape

Faces intense competition from large national hospital chains entering the Eastern Indian market.

Competitive Moat

Moat is built on an established regional brand and strong internal cost controls resulting in RoCE of 23-30% in mature periods. Sustainability depends on maintaining high ARPOB and managing the ramp-up of new facilities.

Macro Economic Sensitivity

Sensitive to healthcare spending and insurance penetration. Ayushman Bharat expansion and GST exemptions on premiums are cited as vital enablers for growth.

Consumer Behavior

Shift toward organized healthcare and specialized treatments is driving higher out-patient volumes (89,802 in H1 FY26 vs 78,909 in H1 FY25).

Geopolitical Risks

Low direct impact, but global supply chain disruptions could affect the cost of imported medical equipment.

⚖️ Regulatory & Governance

Industry Regulations

Subject to Clinical Establishment Acts and government-mandated price caps on cardiac stents, knee implants, and other essential medical devices.

Taxation Policy Impact

Effective tax rate was approximately 30% in H1 FY26 (INR 7.9 Cr tax on INR 26.2 Cr PBT).

⚠️ Risk Analysis

Key Uncertainties

Ramp-up time for the Raipur hospital poses a risk to consolidated profitability; a failure to reach 25% occupancy within 15 months could lead to sustained EBITDA losses.

Geographic Concentration Risk

High concentration with significant revenue derived from West Bengal and Tripura, making the company vulnerable to regional economic or regulatory shifts.